Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[beta-blocker in hypertension]

K Takeuchi1, N Nushiro, K Tsunoda

  • 1Tohoku University School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|August 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Different thresholds of HSP70 and HSC70 heat shock mRNA induction in post-ischemic gerbil brain.

Brain research·1992
Same author

[Mechanism of renin release and cellular action of angiotensin II].

Nihon Naibunpi Gakkai zasshi·1992
Same author

Ras (CXXX) and Rab (CC/CXC) prenylation signal sequences are unique and functionally distinct.

The Journal of biological chemistry·1992
Same author

Isolation of complementary DNAs for heat shock protein (HSP) 70 and heat shock cognate protein (HSC) 70 genes and the expressions in post-ischaemic gerbil brain.

Neurological research·1992
Same author

[DNA typing of HLA-class II genes in idiopathic nephropathy].

Nihon rinsho. Japanese journal of clinical medicine·1992
Same author

Effect of slow release nifedipine tablets in patients with essential hypertension.

Arzneimittel-Forschung·1992
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Beta-blockers effectively lower blood pressure and are a first-line hypertension treatment. Further large-scale trials are needed to confirm their superiority over other antihypertensive drugs.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Context:

  • Beta-blockers are a widely used class of drugs for managing hypertension.
  • Current guidelines recommend beta-blockers as a first-line treatment for high blood pressure.

Purpose:

  • To review the properties and efficacy of beta-blockers in hypertension management.
  • To assess the current evidence supporting the use of beta-blockers compared to other antihypertensive agents.

Summary:

  • Beta-blockers exhibit varying selectivity for beta-receptors and some possess alpha-receptor activity.
  • While effective in reducing blood pressure, large-scale clinical trials have not definitively proven their superiority over other antihypertensive drug classes.
  • Fixed-dose combinations of beta-blockers with calcium channel blockers show greater efficacy than combinations with diuretics.

Related Experiment Videos

Impact:

  • Highlights the need for further robust clinical trials to establish definitive evidence for beta-blocker superiority in hypertension treatment.
  • Informs clinical practice regarding the selection of antihypertensive agents and combination therapies.